Depemokimab & Tzield Among 10 New EU Filings

 
• By Neena Brizmohun

GSK’s depemokimab, if approved, could become the first ultra-long-acting drug for treating asthma and chronic rhinosinusitis with nasal polyps. Meanwhile, Sanofi’s teplizumab, which the US approved as the first disease-modifying therapy for type 1 diabetes in 2022, has now been filed for review by the European Medicines Agency.

Business team analyzing income charts and graphs with modern laptop computer.
The EMA has started reviewing marketing applications for a new batch of drugs (Shutterstock)

More from EU CHMP

More from Approvals